CD8A and neoplasm: Despite clinical evidence supporting its benefit, there is still insufficient understanding of the active compounds in SSG and their underlying mechanisms, which limits its broader clinical application.<h4>Methods</h4>Lewis lung carcinoma (LLC) tumor-bearing mouse model was established to assess the efficacy of combined SSG and anti-PD-1 therapy in vivo, and myeloid-derived suppressor cells (MDSC) and CD8<sup>+</sup>T cells were isolated for in vitro co-culture experiments, while pathological examination was conducted using hematoxylin and eosin (HE).